Society of Gynecologic Oncology Annual Meeting on Women’s Cancer (SGO)

The REFRαME-O1 trial improved response in patients with FRα–positive platinum-resistant ovarian cancer, including those with low to medium expression when given luveltamab tazevibulin.

No deaths or significant adverse effects were reported in the screened population among those who received hysteroscopic resection for endometrial cancer.

Mirvetuximab soravtansine additionally showcased PFS, ORR, and DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.

The phase 2 trial is currently accruing additional patients with advanced mesonephric gynecologic cancer for treatment with avutometinib/defactinib.

The KEYLYNK-001 trial found improved PFS among patients with advanced ovarian cancer given pembrolizumab/olaparib.

Combining zimberelimab with lenvatinib produced a manageable safety profile among patients with advanced cervical cancer in a phase 2 trial.

Although there was no statistical significance in survival data, afuresertib/paclitaxel improved PFS vs paclitaxel in patients with the pAKT biomarker.

Cadonilimab plus lenvatinib appeared to have a manageable safety profile in a phase 2 trial.

Despite similar 36-week results, chemoradiation showed a statistically significant difference in QOL scores at 3 and 7 weeks vs radiation therapy alone.

Adding maintenance olaparib to durvalumab/chemotherapy in pMMR endometrial cancer improved PFS among those with detectable ctDNA at baseline.

Second interim analysis results from the KEYNOTE-A18 trial show continued efficacy of pembrolizumab/CCRT in those with locally advanced cervical cancer.

The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.

A phase 1b evaluating NXP800 in platinum-resistant ARID1A-mutated ovarian cancer is open for enrollment in the United Kingdom and the United States.

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Findings from the phase 2 RAMP 201 trial highlight responses with avutometinib/defactinib in those with KRAS-mutated low-grade serous ovarian cancer and other patient subgroups.

Several patients with TP53 Y220C–mutated ovarian cancer experience tumor shrinkage following treatment with rezatapopt in the phase 1/2 PYNNACLE study.

Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.

Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.

Nab-Sirolimus appears to produce responses in patients with perivascular epithelioid sarcoma regardless of TSC1/TSC2 mutation status.

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.

Data from the DUO-E trial support potential new durvalumab-based treatment options for patients with advanced or recurrent endometrial cancer.

Data from the phase 3 LEAP-001 study support lenvatinib plus pembrolizumab as an active combination for endometrial cancer.

Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.

SEER data showed that Black patients endometrioid endometrial carcinoma had higher 5-year cancer-related death rates compared with their White counterparts.

A phase 2 trial showed favorable antitumor activity when tislelizumab plus chemotherapy was used for patients with locally advaned cervical cancer.

Patient reported outcomes from the phase 3 MIRASOL trial showed improvement when mirvetuximab was used vs standard of care in folate receptor-alpha positive ovarian cancer resistant ovarian cancer.

The phase 2/3 NRG-GY005 trial assessing olaparib plus dediranib did not improve survival vs standard of care in ovarian cancer.

Study finds social determinants of health linked to variations in cervical cancer rates.

The survival benefit with dostarlimab/chemotherapy was deemed unprecedented in patients with microsatellite instability high primary advanced or recurrent endometrial cancer.

Results from the KEYNOTE-868 trial showed a favorable benefit of pembrolizumab plus chemotherapy across endometrial cancer subgroups.